PMID- 22941038
OWN - NLM
STAT- MEDLINE
DCOM- 20130502
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 62
IP  - 3
DP  - 2013 Mar
TI  - MGN-3 arabinoxylan rice bran modulates innate immunity in multiple myeloma 
      patients.
PG  - 437-45
LID - 10.1007/s00262-012-1344-z [doi]
AB  - Dendritic cells (DCs) and natural killer (NK) cells are central components of 
      innate immunity for controlling tumor growth. The therapeutic effects of certain 
      anti-myeloma drugs are partially mediated by targeting the innate immune 
      response. In addition, novel types of natural compounds have been developed that 
      efficiently modulate the activity of both the cellular and humoral compartments 
      of immunity. MGN-3 is known as an activator of natural killer cells, inducer of 
      apoptosis and cytokine production, and modulator of dendritic cell maturation and 
      differentiation in vitro. We have performed a randomized, placebo-controlled 
      study to examine the effects of MGN-3 on innate immune system parameters in 48 
      multiple myeloma patients. We performed immunophenotypic analysis of peripheral 
      blood samples, determined NK cell activity, and assessed the cytokine profiles of 
      plasma before and during 3 months of treatment. The results demonstrate a clear 
      increase in NK activity in MGN-3-treated patients compared to the placebo group, 
      an increased level of myeloid DCs in peripheral blood, and augmented 
      concentrations of T helper cell type 1-related cytokines. The present study 
      suggests that MGN-3 may represent an immunologically relevant product for 
      activating innate immunity in multiple myeloma patients and warrants further 
      testing to demonstrate clinical efficacy.
FAU - Cholujova, Dana
AU  - Cholujova D
AD  - Cancer Research Institute SAS, Vlarska 7, 833 91, Bratislava, Slovakia. 
      dana.cholujova@savba.sk
FAU - Jakubikova, Jana
AU  - Jakubikova J
FAU - Czako, Branislav
AU  - Czako B
FAU - Martisova, Michaela
AU  - Martisova M
FAU - Hunakova, Luba
AU  - Hunakova L
FAU - Duraj, Jozef
AU  - Duraj J
FAU - Mistrik, Martin
AU  - Mistrik M
FAU - Sedlak, Jan
AU  - Sedlak J
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20120902
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Cytokines)
RN  - 0 (Xylans)
RN  - 0 (polysaccharide MGN3)
RN  - 9040-27-1 (arabinoxylan)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Cytokines/metabolism
MH  - Dendritic Cells/drug effects/*immunology
MH  - Female
MH  - Humans
MH  - Immunity, Innate/*drug effects
MH  - Killer Cells, Natural/drug effects/*immunology
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/drug therapy/*immunology
MH  - Oryza/chemistry
MH  - Xylans/*pharmacology
PMC - PMC11029664
COIS- J.S. has received research funding from Daiwa Pharmaceutical. The remaining 
      authors declare no competing conflicts of interest.
EDAT- 2012/09/04 06:00
MHDA- 2013/05/03 06:00
PMCR- 2012/09/02
CRDT- 2012/09/04 06:00
PHST- 2012/02/27 00:00 [received]
PHST- 2012/08/14 00:00 [accepted]
PHST- 2012/09/04 06:00 [entrez]
PHST- 2012/09/04 06:00 [pubmed]
PHST- 2013/05/03 06:00 [medline]
PHST- 2012/09/02 00:00 [pmc-release]
AID - 1344 [pii]
AID - 10.1007/s00262-012-1344-z [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2013 Mar;62(3):437-45. doi: 10.1007/s00262-012-1344-z. 
      Epub 2012 Sep 2.